Why the study?
What is the distribution of prothrombin time in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban therapy?
What is the distribution of prothrombin time in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban therapy?
In Japanese patients with nonvalvular atrial fibrillation taking rivaroxaban, prothrombin time values vary widely and show obscure time-dependence in routine outpatient sampling.
PT variability with obscure time-dependence cautions against routine outpatient monitoring in rivaroxaban-treated AF; leaves open value of timed sampling in future studies.
BACKGROUND: Prothrombin time (PT) distribution in Japanese nonvalvular atrial fibrillation (NVAF) patients under rivaroxaban therapy remains to be clarified. METHODS AND RESULTS: Between May 2012 and July 2013, 115 NVAF patients received rivaroxaban (PT was measured in 94; reagent: recombiplastin). In these patients, (1) PT values were distributed widely from patient to patient and from peak to trough, (2) the time-dependence was obscure with sampling at any time in the outpatient clinic, and (3) the incidence of adverse events was too low for analyzing the relation with PT. CONCLUSIONS: We report the distribution of PT for Japanese NVAF patients under rivaroxaban therapy in real-world clinical practice.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: